Johnson & Johnson (JNJ)
Johnson & Johnson: A Sell-Rated Dividend King
Johnson & Johnson (JNJ) is showing signs of a topping pattern with negative divergences in momentum indicators, suggesting potential price weakness ahead. The stock is expensive based on forward P/E and free cash flow yield, with poor growth prospects and negative earnings revisions. Despite favorable seasonality, JNJ may underperform in a risk-on market environment as defensive sectors lag.
J&J talc subsidiary files third bankruptcy case in attempt to resolve cancer lawsuits
CNBC's Becky Quick reports on the latest news.
Is Johnson & Johnson Stock a Buy?
Johnson & Johnson is capturing strong demand across its pharmaceutical and medtech portfolio. New product launches and an extensive pipeline of candidate drugs support a positive growth outlook.
J&J subsidiary files for bankruptcy to advance $8 billion talc settlement
A Johnson & Johnson subsidiary filed for bankruptcy for a third time on Friday as the healthcare giant seeks to advance an approximately $8 billion proposed settlement that would end tens of thousands of lawsuits alleging that the company's baby powder and other talc products caused cancer.
J&J's Rybrevant Receives FDA Nod for Expanded Use in NSCLC
With this approval, JNJ's Rybrevant is now approved for a total of four indications in the United States.
Pick Disney Over Johnson & Johnson Stock
Given its attractive valuation, we believe that Disney stock (NYSE: DIS) is currently a better pick than the pharmaceuticals bellwether – Johnson & Johnson stock (NYSE: JNJ). The decision to invest often comes down to finding the best stocks within the scope of certain characteristics that suit an investment style.
Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider
Johnson & Johnson (JNJ) closed the most recent trading day at $166.99, moving +0.89% from the previous trading session.
J&J gets $260 mln talc verdict overturned in Oregon, new trial ordered
An Oregon judge has overturned a $260 million verdict against Johnson & Johnson in a lawsuit brought by a woman who said she got mesothelioma, a deadly cancer linked to asbestos exposure, from inhaling the company's talc powder, the company said on Monday.
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
FDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis
With this latest approval, JNJ's Tremfya is approved for a total of three immunology indications.
How To Earn $500 A Month From Johnson & Johnson Stock
On Tuesday, Johnson & Johnson JNJ announced results from the open-label Phase 2 SKIPPirr study, which evaluated additional prophylactic strategies to reduce the incidence of infusion-related reactions (IRRs) with intravenous (IV) Rybrevant (amivantamab-vmjw) in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations.
US FDA expands J&J's psoriasis drug for inflammatory bowel disease
The U.S. Food and Drug Administration has allowed the expanded use of Johnson & Johnson's drug, Tremfya, to treat adults with a type of chronic inflammatory bowel disease, the company said on Wednesday.
